标题
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 16, Pages 1649-1676
出版商
Springer Science and Business Media LLC
发表日期
2020-08-29
DOI
10.1007/s40265-020-01379-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-associated hyperglycaemia in patients with HIV
- (2020) Mohammed Lamorde et al. Lancet HIV
- Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
- (2020) Anthony T. Podany et al. CLINICAL PHARMACOKINETICS
- Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial
- (2020) Kenneth Kintu et al. Lancet HIV
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
- (2019) Jose I. Bernardino et al. PLoS One
- Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
- (2019) JM Llibre et al. HIV MEDICINE
- Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial
- (2019) Kelly E Dooley et al. CLINICAL INFECTIOUS DISEASES
- Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks
- (2019) Rima K. Acosta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors
- (2019) Christian Hoffmann et al. AIDS REVIEWS
- Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077
- (2019) Raphael J Landovitz et al. CLINICAL INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
- (2019) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) Hans-Jürgen Stellbrink et al. Lancet HIV
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) David A Wohl et al. Lancet HIV
- Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
- (2019) Michael Aboud et al. Lancet HIV
- Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a 2-Drug Antiretroviral Therapy for HIV-1 Infection
- (2019) Marta Boffito et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
- (2019) Thomas Theo Brehm et al. MEDICINE
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
- (2019) Catriona Waitt et al. PLOS MEDICINE
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- 2489. Adverse Events with Biktarvy: Post-Marketing Study
- (2019) Edwin Hayes et al. Open Forum Infectious Diseases
- Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection
- (2019) Pedro Cahn et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Adverse drug reactions to integrase strand transfer inhibitors
- (2018) Katherine J. Lepik et al. AIDS
- Dolutegravir and metformin
- (2018) Dario Cattaneo et al. AIDS
- Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
- (2018) Nikki Mulligan et al. AIDS
- Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
- (2018) Edwin DeJesus et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition
- (2018) Emilie R Elliot et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
- (2018) Ruben van der Galiën et al. CLINICAL PHARMACOKINETICS
- Monitoring anonymous HIV testing in Estonia from 2005 to 2015
- (2018) K Rüütel et al. HIV MEDICINE
- Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection
- (2018) Pedro Cahn et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
- (2018) David R Bakal et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals
- (2018) Andrew M. Hill et al. Current Opinion in HIV and AIDS
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
- (2018) Jeremiah D. Momper et al. AIDS
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2018) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
- (2018) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
- (2018) Dario Cattaneo et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
- (2018) Lise Cuzin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling
- (2018) Rajith K R Rajoli et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting
- (2018) Karen Jacobson et al. MEDICINE
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
- (2018) Raphael J. Landovitz et al. PLOS MEDICINE
- Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
- (2017) Anton Pozniak et al. HIV CLINICAL TRIALS
- Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
- (2017) Jose R. Arribas et al. HIV CLINICAL TRIALS
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Brief Report
- (2017) José R. Arribas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir-induced hyperglycaemia in a patient living with HIV
- (2017) Milena McLaughlin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tolerability of integrase inhibitors in a real-life setting
- (2017) Judit Peñafiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
- (2017) Pedro Cahn et al. Lancet HIV
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- First reported use of elvitegravir and cobicistat during pregnancy
- (2016) Stein Schalkwijk et al. AIDS
- Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
- (2016) Manuel Tsiang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
- (2016) C Hoffmann et al. HIV MEDICINE
- Integrase strand transfer inhibitor-associated diabetes mellitus: A case report
- (2016) Peter S Fong et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals
- (2016) Melissa Herrin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Brief Report
- (2016) David Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
- (2016) Alison J. Rodger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen
- (2016) Wan-Jung Tsai et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
- (2016) Anthony Mills et al. LANCET INFECTIOUS DISEASES
- Antiretroviral Therapy for the Prevention of HIV-1 Transmission
- (2016) Myron S. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Change After Antiretroviral Therapy and Mortality
- (2015) B. Yuh et al. CLINICAL INFECTIOUS DISEASES
- Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
- (2015) Maren I. Blonk et al. CLINICAL INFECTIOUS DISEASES
- Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
- (2015) Walter Dehority et al. DRUGS
- Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
- (2015) AC Achhra et al. HIV MEDICINE
- Brief Report
- (2015) Sharon Walmsley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model
- (2015) Stein Schalkwijk et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
- (2015) Gary David Bowers et al. XENOBIOTICA
- Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients
- (2015) Leonardo Calza et al. Infectious Diseases
- Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
- (2015) Jean-Michel Molina et al. Lancet HIV
- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
- (2014) Jeffrey L. Lennox et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
- (2014) J. M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals
- (2014) Shelley A. McCormack et al. CLINICAL PHARMACOKINETICS
- Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data
- (2014) A. Mills et al. HIV CLINICAL TRIALS
- Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients
- (2014) L. Curtis et al. HIV CLINICAL TRIALS
- Raltegravir Pharmacokinetics During Pregnancy
- (2014) D. Heather Watts et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
- (2014) Eve-Irene Lepist et al. KIDNEY INTERNATIONAL
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
- (2014) Jose R Arribas et al. LANCET INFECTIOUS DISEASES
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
- (2014) Anton Pozniak et al. LANCET INFECTIOUS DISEASES
- Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- (2014) Beatriz Grinsztejn et al. LANCET INFECTIOUS DISEASES
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
- (2013) W. Spreen et al. HIV CLINICAL TRIALS
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
- (2013) B. Hernandez-Novoa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
- (2013) Hasina Samji et al. PLoS One
- Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study
- (2012) D. A. Wohl et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
- (2012) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults
- (2012) Frederick J. Lee et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
- (2012) Kelly E. Dooley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
- (2011) Alain Nguyen et al. AIDS
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Long-Term Safety from the Raltegravir Clinical Development Program
- (2011) Hedy Teppler et al. CURRENT HIV RESEARCH
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A case of rhabdomiolysis associated with raltegravir use
- (2010) Luca Dori et al. AIDS
- Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
- (2010) Esteban Martinez et al. AIDS
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
- (2010) F Croce et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution
- (2010) Mar Masiá et al. JOURNAL OF INFECTION
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Severe rhabdomyolysis associated with raltegravir use
- (2009) Teresa R Zembower et al. AIDS
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000???2006
- (2008) Claire L Townsend et al. AIDS
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination
- (2007) H. Jeong et al. XENOBIOTICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More